ROS Therapeutics Holding ApS: Financial statements 2020
CVR: 39507056
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
ROS Therapeutics Holding ApS (CVR 39507056) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -12,500 and a net result of DKK 3,990,250 compared with DKK -11,963 the year before. Equity in the 2020 report amounted to DKK 4,055,841. The solvency ratio was 94.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -12,500
- Profit/Loss
- DKK 3,990,250
- Equity
- DKK 4,055,841
- Total Assets
- DKK 4,283,847
- Employees
- 1
Official annual report
How creditworthy is ROS Therapeutics Holding ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
ROS Therapeutics Holding ApS has published its annual report for 2019. Gross profit came to DKK -15,000, and the net result was DKK -11,963.
As of May 10, 2020, SPORCON LIFESCIENCE ADVISORS ApS is registered as an owner of ROS Therapeutics Holding ApS with an ownership share of 10%.
About ROS Therapeutics Holding ApS
ROS Therapeutics Holding ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Hanne Damgaard Jensen. The company is owned by SPORCON LIFESCIENCE ADVISORS ApS and HDJ & LEJ Invest ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -10,750 and a net result of DKK -26,512 compared with DKK -14,342 the year before. Equity in the 2025 report amounted to DKK -116,804.
